Repligen (RGEN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $155 million, up 10% year-over-year, driven by strong CDMO (~20% growth), filtration, and new modalities performance.

• Order intake outpaced sales by 4%, with robust performance in the Americas and Asia ex-China, while China remained a headwind.

• Gross margin improved to 50.0%-50.7% in Q3 2024, reflecting higher productivity and absence of prior year restructuring charges.

• Net loss for Q3 2024 was $0.7 million, mainly due to higher SG&A and stock compensation from the CEO transition.

• Announced pending acquisition of Tantti Laboratory Inc. and opened the Repligen Training and Innovation Center.

Financial highlights

• Q3 2024 revenue was $155 million, up 10% year-over-year; nine-month revenue was $467 million, up 0.2%.

• Adjusted gross profit was $78 million (50.7% margin); GAAP gross profit $77 million (50.0% margin).

• Adjusted net income was $24 million; GAAP net loss was $0.7 million; adjusted EPS $0.43, GAAP EPS $(0.01).

• Cash and short-term investments at quarter-end were $784 million, up from $751 million at year-end 2023.

• Working capital increased to $1,023 million from $946 million at year-end 2023.

Outlook and guidance

• Full-year 2024 revenue guidance narrowed to $630–$639 million, including $7 million incremental revenue from a restatement.

• Adjusted operating margin forecasted at 12.5%-13.5%; adjusted EBITDA margin at 17.5%-18.5%.

• Adjusted net income guidance is $85–$89 million; adjusted EPS $1.50–$1.58; effective tax rate expected at 20%.

• Management expects operating expenses to rise as the company expands bioprocessing and new product lines.

• Current cash balances are adequate for at least the next 24 months, absent major acquisitions.